{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:16Z","timestamp":1793390716299,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.nmd.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:21:41Z","timestamp":1662510101000},"page":"790-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-6729","authenticated-orcid":false,"given":"Linda","family":"Remijn-Nelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-0390","authenticated-orcid":false,"given":"Martijn R.","family":"Tannemaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.09.002_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.09.002_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2022.09.002_bib0003","first-page":"759","article-title":"Case showing the Effect of Prostigmin on Myasthenia Gravis","volume":"28","author":"Walker","year":"1935","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.nmd.2022.09.002_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2004-829584","article-title":"A history of treatments for myasthenia gravis","volume":"24","author":"Keesey","year":"2004","journal-title":"Semin Neurol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.1954.03690290011004","article-title":"Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide","volume":"155","author":"Osserman","year":"1954","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.nmd.2022.09.002_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1056\/NEJM195408122510706","article-title":"Pyridostigmin (mestinon) in the treatment of myasthenia gravis","volume":"251","author":"Schwab","year":"1954","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2022.09.002_bib0007","first-page":"98","article-title":"Mestinon (pyridostigmine bromide) in myasthenia gravis","volume":"75","author":"Schwarz","year":"1956","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.nmd.2022.09.002_bib0008","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.1956.02960380004002","article-title":"Treatment of myasthenia gravis with mestinon bromide","volume":"160","author":"Tether","year":"1956","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.nmd.2022.09.002_bib0009","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.4.10.762","article-title":"Mestinon in the treatment of myasthenia gravis","volume":"4","author":"Westerberg","year":"1954","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.09.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006986.pub3","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2022.09.002_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s004150050059","article-title":"Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients","volume":"244","author":"Beekman","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0012","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","article-title":"Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis","volume":"37","author":"Punga","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.09.002_bib0013","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.nmd.2021.05.006","article-title":"Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"31","author":"Ruiter","year":"2021","journal-title":"Neuromuscular disorders : NMD"},{"key":"10.1016\/j.nmd.2022.09.002_bib0014","unstructured":"CBG. Summary of Product Characteristics: pyridostigmine. 1990 29 oktober 2020 [cited 16-06-2021]."},{"key":"10.1016\/j.nmd.2022.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.09.002_bib0016","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.09.002_bib0017","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2022.09.002_bib0018","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.nmd.2022.09.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.09.002_bib0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mus.27331","article-title":"Gender differences in clinical outcomes in myasthenia gravis: a prospective cohort study","volume":"64","author":"Thomsen","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.09.002_bib0021","first-page":"1254","article-title":"Sex-based differences in drug activity","volume":"80","author":"Whitley","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.nmd.2022.09.002_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.nmd.2022.09.002_bib0023","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2022.09.002_bib0024","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.09.002_bib0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.nmd.2021.04.002","article-title":"Prevalence and associated factors of fatigue in autoimmune myasthenia gravis","volume":"31","author":"Ruiter","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.09.002_bib0026","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0027","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archopht.1959.04220060057010","article-title":"Evaluation of ocular signs and symptoms in myasthenia gravis","volume":"62","author":"Schlezinger","year":"1959","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2022.09.002_bib0029","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01675867","article-title":"The ocular signs and symptoms of myasthenia gravis","volume":"52","author":"Oosterhuis","year":"1982","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular Myasthenia","volume":"36","author":"Al-Haidar","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2022.09.002_bib0031","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0032","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2022.09.002_bib0033","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622006526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622006526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:42Z","timestamp":1760775162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622006526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0960896622006526"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.09.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}